Compass Pathways shares surge on cash runway expectations

Published 27/02/2025, 17:22
Compass Pathways shares surge on cash runway expectations

LONDON - Compass Pathways plc (NASDAQ:CMPS) shares jumped 9.5% after the biotechnology company focused on mental health treatments reported fourth quarter earnings in line with expectations and provided an update on its cash position and clinical trial timelines.

The company reported a fourth quarter loss of $0.63 per share, matching analyst estimates. Net loss for the quarter was $43.3 million, compared to $32.5 million in the same period last year. Research and development expenses increased to $32.1 million from $27.1 million YoY, primarily due to advancing phase 3 clinical trials for its COMP360 psilocybin treatment.

Compass ended 2024 with $165.1 million in cash and cash equivalents. The company raised an additional $150 million gross in January 2025, extending its cash runway. Management expects the current cash position to fund operations through the planned 26-week data readout from the COMP006 study in treatment-resistant depression, expected in the second half of 2026.

"We are excited that the first data readout from our pivotal phase 3 COMP360 program in treatment resistant depression continues on track with top-line 6-week data expected next quarter," said CEO Kabir Nath.

The company reaffirmed that top-line data from its phase 3 COMP005 trial in treatment-resistant depression remains on track for the second quarter of 2025. Compass is also advancing plans for a late-stage clinical program in post-traumatic stress disorder following promising phase 2a data last year.

For full year 2025, Compass projects net cash used in operating activities between $120 million to $145 million.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.